Price
No data yet.
Social Signal Score
Analyst Ratings
52 analystsRevenue
$1.46B+8253.88%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yvonne L. Greenstreet
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,500
- Beta
- 0.27
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 3.48
Financials
Revenue
$1.46B+8253.9%Net Income
$2.17BEBITDA
$394.66MFree Cash Flow
$271.15MEPS (diluted)
$15.72Shares Outstanding (diluted)
138.04M+60.8%Operating Expenses
$750.54MCash & Debt
$3.59BReturn of Capital
$0.00Revenue by Segment (annual)
$3.71BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.71B | $313.75M | $2.39 |
| 2024 | $2.25B | $-278.16M | $-2.18 |
| 2023 | $1.83B | $-440.24M | $-3.52 |
| 2022 | $1.04B | $-1.13B | $-9.30 |
| 2021 | $844.29M | $-852.82M | $-7.20 |
| 2020 | $492.85M | $-858.28M | $-7.46 |
| 2019 | $219.75M | $-886.12M | $-8.11 |
| 2018 | $74.91M | $-761.50M | $-7.57 |
| 2017 | $89.91M | $-490.87M | $-5.42 |
| 2016 | $47.16M | $-410.11M | $-4.79 |
| 2015 | $41.10M | $-290.07M | $-3.45 |
| 2014 | $50.56M | $-360.39M | $-4.85 |
| 2013 | $47.17M | $-89.22M | $-1.45 |
| 2012 | $66.72M | $-106.01M | $-2.11 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.52
- Implied price
- $63.34
- Return from $143.82
- -15.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $31.49 — -78.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -29.0% | -25.7% | -23.0% | -20.6% | -18.4% |
| 3.0% | -25.4% | -22.0% | -19.1% | -16.5% | -14.3% |
| 8.0% | -21.7% | -18.2% | -15.1% | -12.5% | -10.1% |
| 13.0% | -18.1% | -14.4% | -11.2% | -8.4% | -5.9% |
| 18.0% | -14.5% | -10.6% | -7.3% | -4.4% | -1.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
20-79.66%Social Signal Score
Mentions (49)
- Newsbusinesswire.com·3d ago·Negative
…, the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has approved Livsayis™ (cemdisiran), an Alnylam-discovered RNAi therapeutic that was developed and will be commercialized by Regeneron, for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acety…
View source ↗ - Newsseekingalpha.com·4d ago·Positive
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies Global Healthcare Conference 2026 Transcript Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - News (Marketaux)gurufocus.com·5d ago·Positive
Alnylam Pharmaceuticals (ALNY) Surpasses Q3 Earnings Expectations with Strong Market Performance On November 17, 2026, Alnylam <[+315 characters]
View source ↗ - Newsbusinesswire.com·13d ago·Negative
…ive-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the American Heart Association (AHA) Scientific Sessions 2026, adding to the robust body of evidence demonstrating the strength of RNAi-powered TTR silencing with AMVUTTRA® (vutrisiran). The analyses, including data from the HELIOS-B Phase 3 two-year open-labe…
View source ↗ - News (RSS)investing·16d ago·Neutral
Alnylam Pharmaceuticals stock hits 52-week low at $155.22
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Brown Advisory Large-Cap Sustainable Growth Strategy Q3 2026 Holdings Performance Consensus EPS estimates for 2026 and 2027 revised upward by an average of 6.0% and 4.3%, respectively, during the third quarter. Microsoft Corporation had one of its strongest quarterly stock performances since 1998. Snowflake's strong stock performance was driven by a third consecutive quarter of product revenue growth acceleration.
View source ↗ - News (RSS)investing·18d ago·Positive
Alnylam authorizes $1 billion share buyback program
View source ↗ - Newsbusinesswire.com·18d ago·Neutral
Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share repurchase program and that the Company will transition to new commercial leadership as it enters its next phase of growth. "Today we announced two important decisions, both of which demonstrate our conviction in…
View source ↗ - News (RSS)seekingalpha·22d ago·Neutral
Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease - Slideshow
View source ↗ - News (Marketaux)seekingalpha.com·22d ago·Neutral
Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease - Slideshow (NASDAQ:ALNY) 2026-10-30 Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease - Slideshow (NASDAQ:ALNY) 2026-10-30
View source ↗ - Newszacks.com·23d ago·Positive
ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns Alnylam's shares fall 25% despite Q3 beat as slower Amvuttra patient starts and demand concerns weigh on investor sentiment.
View source ↗ - News (RSS)seekingalpha·23d ago·Neutral
Alnylam Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·24d ago·Neutral
Alnylam Pharmaceuticals Q3 Earnings Call Highlights Alnylam Pharmaceuticals NASDAQ: ALNY reported third-quarter 2026 global net product revenue of approximately $1.3 billion, up 52% from a year earlier and 10% sequentially, as growth in its transthyretin, or TTR, franchise continued to drive results.
View source ↗ - Newszacks.com·24d ago·Positive
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $16.26 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.9 per share a year ago.
View source ↗ - Newszacks.com·25d ago·Neutral
Alnylam (ALNY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures Get a deeper insight into the potential performance of Alnylam (ALNY) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
View source ↗ - News (RSS)seekingalpha·26d ago·Positive
Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript
View source ↗ - News (RSS)seekingalpha·27d ago·Positive
Alnylam: Amvuttra Growth And Brezosiran Strengthen The Bull Case
View source ↗ - Newsmarketbeat.com·27d ago·Neutral
Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial Alnylam Pharmaceuticals NASDAQ: ALNY outlined early clinical data for brezosiran, an investigational RNA interference therapy for Huntington's disease, reporting dose-dependent reductions in cerebrospinal fluid mutant huntingtin after a single intrathecal dose and plans to begin a placebo-controlled pivotal study in 2027, pending regulatory alignment.
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Alnylam: Amvuttra Growth And Brezosiran Strengthen The Bull Case Alnylam Pharmaceuticals, Inc.'s shares remain under pressure. Meanwhile, on October 23, Alnylam reported promising clinical data for brezosiran, its investigational treatment for Huntington's disease. Moreover, second-quarter Amvuttra sales surged 105.7% year-on-year to approximately $1.1 billion.
View source ↗ - News (RSS)zerohedge·30d ago·Neutral
Futures Wobble After AI Bloodbath As Brent Hits $114, France Braces For Moody's Futures Wobble After AI Bloodbath As Brent Hits $114, France Braces For Moody's US futures are lower, erasing a modest overnight bounce, as markets scramble after Thursday's violent AI liquidation while oil rises again: Brent hit the highest level since May after the Houthis fired another missile at Riyadh and an IRGC official declared traffic of "illicit" vessels through Hormuz "completely stopped" (contradicted by
View source ↗ - Newsbusinesswire.com·30d ago·Neutral
…iran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington's disease, which will be developed under the International Nonproprietary Name (INN) brezosiran (bre-ZOH-sir-an). The data wer…
View source ↗ - Newsfool.com·32d ago·Negative
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? Alnylam's stock has plunged more than 40% this year, but the company's financials look great. Investors have been spooked by a guidance cut and a rival drug's clinical setback.
View source ↗ - Newsfool.com·43d ago·Positive
Alnylam vs. Ionis: Here's the Better Bad-News Buy Alnylam cut its full-year revenue guidance due to slower-than-expected sales for Amvuttra. Ionis experienced two pipeline setbacks on the same day in July.
View source ↗ - Newsglobenewswire.com·48d ago·Negative
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsglobenewswire.com·51d ago·Negative
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsseekingalpha.com·55d ago·Neutral
Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform Alnylam Pharmaceuticals, Inc. shares have fallen 18% amid concerns over its ATTR-CM franchise following AstraZeneca/Ionis trial failure. I see pessimism as understandable but overdone; nucresiran's superior TTR knockdown and trial design differences support a credible case for TRITON-CM success. Even if TRITON-CM fails, Amvuttra's first-line share gains and Alnylam's diverse pipeline mitigate downside risk.
View source ↗ - Newszacks.com·55d ago·Neutral
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
View source ↗ - Newsfool.com·55d ago·Positive
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. Wall Street analysts are overwhelmingly bullish about Alnylam. The stock's attractive valuation and the company's growth prospects appear to support their enthusiasm.
View source ↗ - News (RSS)seekingalpha·57d ago·Positive
Alnylam Needs Stronger Amvuttra Execution To Justify More Upside
View source ↗ - News (Marketaux)seekingalpha.com·57d ago·Positive
Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY) Although Alnylam Pharmaceut[+312 characters]
View source ↗ - Newsmarketbeat.com·63d ago·Positive
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook Alnylam Pharmaceuticals NASDAQ: ALNY highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook.
View source ↗ - Newsmarketbeat.com·64d ago·Neutral
Alnylam's Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial Alnylam Pharmaceuticals NASDAQ: ALNY outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with twice-yearly dosing for people with uncontrolled hypertension and elevated cardiovascular risk.
View source ↗ - News (RSS)seekingalpha·66d ago·Positive
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript
View source ↗ - News (RSS)seekingalpha·66d ago·Neutral
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control - Slideshow
View source ↗ - Newsseekingalpha.com·66d ago·Positive
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript
View source ↗ - Newsseekingalpha.com·75d ago·Positive
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·82d ago·Neutral
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
View source ↗ - News (Marketaux)gurufocus.com·84d ago·Neutral
ALNY Looks 55.6% Undervalued on GF Value™ Amid New Cardiovascular RNAi Data On August 30, 2026, Alnylam <em[+259 characters]
View source ↗ - News (RSS)seekingalpha·84d ago·Negative
Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case
View source ↗ - Newsbusinesswire.com·84d ago·Negative
…gth in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patien…
View source ↗ - Newsbusinesswire.com·90d ago·Negative
…h in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and hypertension programs at the European Society of Cardiology (ESC) Congress 2026, taking place August 28-31, 2026, in Munich, Germany. These presentations add to …
View source ↗ - Newsglobenewswire.com·94d ago·Negative
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
View source ↗ - Newsglobenewswire.com·95d ago·Negative
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗ - News (RSS)fool·98d ago·Negative
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.
View source ↗ - Newsfool.com·98d ago·Negative
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing Alnylam's stock has plunged due to a revenue guidance cut and other concerns. However, the full story for this biotech innovator is more positive than meets the eye.
View source ↗ - Newsglobenewswire.com·101d ago·Negative
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Continuing Securities Fraud Investigation BENSALEM, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsglobenewswire.com·102d ago·Negative
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗
Earnings
Thu, Feb 11(in 3 months)
Consensus estimate $1.72 per share
Typical surprise +50.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$16.26 vs $1.66beat
- Thu, Jul 30$1.21 vs $1.63miss
- Thu, Apr 30$1.51 vs $0.87beat
- Thu, Feb 12$0.82 vs $1.16miss
- Thu, Oct 30$1.84 vs $0.56beat
- Thu, Jul 31$-0.51 vs $-0.54beat
Estimates and results for ALNY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALNY officers and directors.
- Bought
- $543k
- Sold
- $7.3m
2 trades
68 trades
- Sigal Charles Elliottbought
- Schulman Amy Wbought
- Supran Bryansold
- Pyott David E Isold
- Pyott David E Isold
- Pyott David E Isold
- Pyott David E Isold
- Pyott David E Isold
30 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Cory Bookersenate · NJ · disclosed Sep 9, 2026 (29d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$15,001 - $50,000
- Josh Gottheimerhouse · NJ05 · disclosed Feb 15, 2024 (17d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Feb 15, 2024 (35d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 7, 2024 (27d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (26d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (24d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Jan 3, 2023 (28d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 16, 2022 (18d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Dec 9, 2020 (26d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed May 13, 2020 (37d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 16, 2018 (29d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 2, 2018 (123d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
